Go or no go? Seagen's Padcev eyes FDA approval
Seres and Pfizer are also set for upcoming FDA Pdufa decisions, and a panel is scheduled for Astrazeneca and Merck’s Lynparza.
Biotech’s near-term key catalysts
Important data reveals are expected from Madrigal, Arrowhead and Ascendis, with details from Biogen and Eisai due at a conference.
Cytokine players keep the faith
The demise of Nektar’s bempegaldesleukin has not stemmed the tidal wave of companies developing IL-2 and IL-15 therapies.
Why some biotechs should never launch a drug
Acacia just became the latest biotech to suffer the curse of seeing one of its drugs approved.
Novo makes a rare disease push
More deals could be in the offing, but gene therapy does not appear to be a big focus.
Biotech’s important first-quarter data
Kodiak, Biomarin and Argenx prepare for clinical catalysts.
Biggest unpartnered assets: Argenx nears crunch time
Amid cautionary tales of other highly valued unpartnered assets, efgartigimod approaches its US date with destiny.